Hochhaus A.,Universitatsklinikum Jena |
Duyster J.,TU Munich |
Haferlach T.,MLL Munchner Leukamie Labor GmbH |
Lange T.,University of Leipzig |
And 3 more authors.
Onkologe | Year: 2010
Chronic myeloid leukemia (CML) is a life-threatening disease. The introduction of imatinib, a tyrosine kinase inhibitor, substantially improved the prognosis for long-term survival with CML. Imatinib is significantly more effective than hydroxyurea or interferon-α and is now established as the standard first-line therapy for CML patients in the chronic phase. Nevertheless, according to recent surveys, almost one-third (25-32%) of all CML patients in Germany are still being treated with hydroxyurea. Most of these are elderly CML patients >60 years old, from whom imatinib treatment is withheld on the basis of age. Various studies have shown that imatinib is also effective in elderly CML patients and is well tolerated. This report gives a critical review of existing data on the treatment of elderly CML patients with imatinib and contains recommendations for first-line therapy for patients in this age group. © Springer-Verlag 2010.
Michallet M.,University of Lyon |
Losem C.,Praxis Fur Onkologie und Hamatologie
Acta Haematologica | Year: 2015
Chemotherapy-induced anaemia is frequent in cancer patients, with severity depending on the extent of the disease and intensity of treatment. Clinical guidelines recommend erythropoietin therapy to treat or prevent anaemia in some oncology/haematology patients being treated with chemotherapy. The patent expiry of the first-generation erythropoietins has led to the development of biosimilar products, i.e. therapeutic proteins exhibiting comparable quality, safety and efficacy to an existing reference biological medicine, the patent of which has expired. This review summarises the available data set supporting the use of one such biosimilar product, epoetin zeta (Retacrit™) in oncology/haematology. The body of evidence supporting the use of epoetin zeta continues to grow, with post-marketing clinical studies underway to evaluate its longer-term clinical efficacy and safety. Biosimilar medicines have the potential to offer cost savings to health care providers, with the assurance of ongoing risk management programmes to ensure patient safety. © 2015 The Author(s)Published by S. Karger AG, Basel.